Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir

Antiviral Therapy

Volumn 14, Issue 7, 2009, Pages 985-993

  Choe, Won Hyeok ^a,b   Hong, Sun Pyo ^c   Kim, Byung Kook ^a   Ko, Soon Young ^a   Jung, Young Kul ^d   Kim, Ji Hoon ^d   Yeon, Jong Eun ^d   Byun, Kwan Soo ^d   Kim, Kyun Hwan ^b,e   Ji, Seung Il ^c   Kim, Soo Ok ^c   Lee, Chang Hong ^a,b   Kwon, So Young ^a,b  

^a Konkuk University Hospital   (South Korea)

^b Konkuk University   (South Korea)

^c GeneMatrix Inc   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Konkuk University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HEPATITIS B; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; TREATMENT OUTCOME;

EID: 72249122581     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1417     Document Type: Article

References (34)

1. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. (Pubitemid 43374518)
2. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
3. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97:265-272.
4. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008; 28:167-177. (Pubitemid 351861968)
5. Lok AS. The maze of treatments for hepatitis B. N Engl J Med 2005; 352:2743-2746.
6. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005; 25 Suppl 1:9-19. (Pubitemid 41254589)
7. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751. (Pubitemid 44958517)
8. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43:1385-1391. (Pubitemid 43980117)
9. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45:307-313. (Pubitemid 46374587)
10. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133:1445-1451. (Pubitemid 350047463)
11. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133:1437-1444. (Pubitemid 350029745)
12. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44:1656-1665. (Pubitemid 44953670)
13. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48:3498-3507.
14. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48:99-108. (Pubitemid 351975535)
15. Suzuki F, Toyoda J, Katano Y, et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol 2008; 23:1320-1326.
16. Su CW, Wu JC, Lee SD. Is entecavir ideal for the treatment of lamivudine-refractory chronic hepatitis B? Hepatology 2008; 48:1726-1727.
17. Kamar N, Milioto O, Alric L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86:611-614.
18. Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009; 50:674-683.
19. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drugresistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46:254-265. (Pubitemid 47171942)
20. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat 2007; 14 Suppl 1:29-36. (Pubitemid 47624112)
21. Hong SP, Kim NK, Hwang SG, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004; 40:837-844.
22. Kim HS, Han KH, Ahn SH, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005; 10:441-449.
23. Lee CH, Kim SO, Byun KS, et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006; 130:1144-1152.
24. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55:1488-1495. (Pubitemid 44476796)
25. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010. (Pubitemid 43357804)
26. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020. (Pubitemid 43357805)
27. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49:1503-1504.
28. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9:679-693. (Pubitemid 39434331)
29. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48:747-755.
30. Qi X, Xiong S, Yang H, et al. susceptibility of adefovirassociated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12:355-362. (Pubitemid 46787980)
31. Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10:625-633. (Pubitemid 41224954)
32. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4:936-962. (Pubitemid 44118844)
33. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
34. Choe WH, Kwon SY, Kim BK, et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int 2008; 28:814-820.